logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Pharmaceutical
Filter

Pharmaceutical

Categories

Sectors

Locations

Exchange

营收和利润均表现出色,这只制药股上涨还有另外一个重要原因

Soaring Demand for GLP-1 Drugs Makes Amgen and Regeneron Rising Stars

Aug 15, 2026

Life Science

Druckenmiller’s $613 Million Silent Bet Is Crushing Nvidia — and It’s Not a Tech Stock

The Medical Device Industry Ushers in a Golden Era of Development, with Three Leading Stocks Leading the Market

Aug 14, 2026

Life Science

Inside Johnson & Johnson’s Rare Combination: A 64-Year Dividend Streak Meets a 50% Stock Rally

Inside Johnson & Johnson’s Rare Combination: A 64-Year Dividend Streak Meets a 50% Stock Rally

Aug 13, 2026

Life Science

谷歌云如何重塑Alphabet未来?

Google Pixel Watch 5 Debuts Insulin Resistance Tracking, Ushering Wearables Into the Era of AI-Powered Health Early Warning

Aug 12, 2026

Life Science, Technology

为何礼来能无视关税威胁?国内产能与基因疗法是关键

Why Is Lilly Worth Buying?

Aug 12, 2026

Life Science

AbbVie’s $8 Billion Bet Without Breaking a 53-Year Dividend Streak

AbbVie’s $8 Billion Bet Without Breaking a 53-Year Dividend Streak

Aug 11, 2026

Life Science

联合健康与礼来,谁将引领市场?

Eli Lilly’s New Weight-Loss Drug Receives U.K. Marketing Authorization, Securing Another Milestone in European Market Expansion

Aug 11, 2026

Life Science

AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts

AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts

Aug 10, 2026

Life Science

艾伯维的挑战与机遇:三大关键因素决定未来增长

Unpacking the Investment Value of AbbVie and Abbott in 2026

Aug 8, 2026

Life Science

Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027?

Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027?

Aug 7, 2026

Life Science

Down 46%, Yet Wall Street Predicts a 161% Surge: Would You Bet on This Weight-Loss Drug Stock?

Down 46%, Yet Wall Street Predicts a 161% Surge: Would You Bet on This Weight-Loss Drug Stock?

Aug 6, 2026

Life Science

Lilly’s Q2 Smashes Estimates, Yet the Stock Barely Budges in 2026

Lilly’s Q2 Smashes Estimates, Yet the Stock Barely Budges in 2026

Aug 5, 2026

Life Science

Vertex Tops Q2 Estimates, But Investors Shift Focus to Crinetics Deal Integration

Vertex Tops Q2 Estimates, But Investors Shift Focus to Crinetics Deal Integration

Aug 4, 2026

Life Science

为何艾伯维当前是投资者的不错选择?

AbbVie Lowers Full-Year Profit Guidance, Investor Disappointment Triggers Stock Sell-Off

Aug 1, 2026

Life Science

Novo Nordisk: At 11x P/E, a Golden Entry or a Value Trap?

Novo Nordisk: At 11x P/E, a Golden Entry or a Value Trap?

Jul 31, 2026

Life Science

联合健康与礼来,谁将引领市场?

Bristol-Myers Squibb Beats Estimates in Q2, Stock Outperforms Market on Thursday

Jul 31, 2026

Life Science

Weight-Loss Pipeline in Focus: Viking Therapeutics Could Be the Next Acquisition Target

Weight-Loss Pipeline in Focus: Viking Therapeutics Could Be the Next Acquisition Target

Jul 30, 2026

Life Science

Bullish 上市首日暴涨 84%,Ark Invest 重仓押注加密赛道

Seize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debut

Jul 29, 2026

Life Science

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada